Loading
IARC estimates 3,605 new cancer cases and 2,281 cancer deaths in Mauritania in 2024; the commonest new cancers are breast, prostate and cervix uteri. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Mauritania's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 844 | 48.3 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 404 | 35.6 | Prostate cancer |
| Cervix uteri | 390 | 24.7 | Cervical cancer |
| Liver and intrahepatic bile ducts | 260 | 8.5 | Hepatocellular carcinoma |
| Colorectum | 210 | 7.3 | Colorectal cancer |
| Stomach | 137 | 5.0 | Gastric & gastro-oesophageal junction cancer |
| Ovary | 99 | 6.1 | Ovarian cancer |
| Non-Hodgkin lymphoma | 81 | 2.1 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 79 | 2.2 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Pancreas | 75 | 2.8 | Pancreatic ductal adenocarcinoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Breast | 399 | 23.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 258 | 22.5 | Prostate cancer |
| Cervix uteri | 239 | 15.4 | Cervical cancer |
| Liver and intrahepatic bile ducts | 234 | 7.8 | Hepatocellular carcinoma |
| Colorectum | 118 | 4.4 | Colorectal cancer |
| Stomach | 110 | 4.2 | Gastric & gastro-oesophageal junction cancer |
| Pancreas | 75 | 2.8 | Pancreatic ductal adenocarcinoma |
| Ovary | 67 | 4.4 | Ovarian cancer |
| Leukaemia | 58 | 1.7 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Trachea, bronchus and lung | 52 | 2.0 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
No trial record in OnCo lists a site in Mauritania. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Mauritania.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Mauritania is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Mauritania is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.